Citation: The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. New Engl J Med 2009; 360:1283-97. Lead Author: Simon Finfer, sfinfer@med.usyd.edu.au Three part clinical question: Patients: Adult ICU patients (6, 104) in Australia, New Zealand and Canada. Intervention: Intensive vs conventional blood glucose control. Outcomes: Primary -90-day all-cause mortality. Secondarysurvival time during the first 90 days, cause-specific death, duration of mechanical ventilation and renal replacement therapy, and duration of ICU and hospital stay. Tertiary -death from any cause with 28 days, place of death, incidence of new organ failure, positive blood cultures, blood transfusion, volume of blood transfusion. Serious adverse eventsincidence and severity of hypoglycaemia (blood glucose ≤2.2 mmol/L).
Search terms: Insulin, blood glucose, ICU, RCT, outcome, mortality.
The study: Multi-centre, open label, randomised controlled trial with intention-to-treat analysis.
The study patients: Adult medical or surgical ICU patients who, within 24 hours of admission, were predicted to require ICU treatment for three or more consecutive days. An arterial line was in situ or inserted within one hour. Exclusion criteria: Age <18 years, imminent death confirmed by a documented treatment limitation order, diabetic ketoacidosis or hyperosmolar state, previous hypoglycaemia without documented full neurological recovery, high risk of hypoglycaemia, previous enrolment in the study, unable to gain consent, over 24 hours post admission to ICU.
Patients were stratified into the following sub-groups for the purpose of primary outcome group analysis:
Blood glucose management in both control and experimental groups was guided by a specific web-based treatment algorithm. Blood glucose samples were obtained from arterial or central venous lines. Blood glucose measurements were performed initially hourly, then reduced to two-and then four-hourly once insulin infusion, blood glucose concentrations and caloric intake were stable.
The intervention continued until the patient no longer required supplementary enteral or parental nutrition and had started eating, or until ICU discharge or death or completion of the 90-day trial period.
Control group: (n=3,014; 3,012 analysed) Conventional glucose control (target blood glucose of 10.0 mmol/L or less); insulin administered if blood glucose >10.0 mmol/L, adjusted when required to maintain blood glucose between 8-10 mmol/L and discontinued when blood sugar was <8.0 mmol/L. This may merit further study. 6. Did they make any recommendations based on the results and were they appropriate? Yes. A target blood glucose range of 8-10 mmol/L is more appropriate in the ICU setting than 4.5-6.0 mmol/L. 7. Is the study relevant to my clinical practice? Yes. This is the first randomised, controlled study to look at a large, heterogeneous group of critically ill patients in the intensive care setting with a long follow-up period. Insulin administration is commonplace. Many units in the UK have adopted a tight glycaemic control policy following previous studies. 8. What level of evidence does this study represent? 1 + . The authors recognised that the bedside treatment strategies could not be blinded from the treating physicians. Precautions taken to minimise bias included the use of a centralised computerised algorithm to guide glucose control and a feeding regimen protocol with supplementary collection of details pertaining to nutritional support for all patients. 9. What grade of recommendation can I make on this result alone? B. 10.What grade of recommendation can I make when this study is considered along with other available evidence? A. 11.Should I change my practice because of these results? Yes. The findings from this study suggest that in a heterogeneous critical care population, there is no additional benefit to be gained through intensive blood glucose control in those who have been on ICU for more than three days and that the strategy is associated with more severe hypoglycaemic events. A target blood sugar of between 8-10 mmol/L may be more appropriate. In this study, 69% of patients required insulin to achieve this. 12.Should I audit my current practice because of these results? Yes. The evidence: (hypoglycaemia)
